|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 61.62 CNY | +0.60% |
|
-0.74% | +34.25% |
| Dec. 02 | Hengrui Medicine Gets Regulatory Acceptance for Anesthetic Marketing Application | MT |
| Nov. 27 | Hengrui Medicine Gets China Approval for Multiple Drug Trials | MT |
| Capitalization | 410B 57.93B 49.8B 46.65B 43.48B 80.31B 5,214B 87.35B 546B 211B 2,462B 217B 213B 9,003B | P/E ratio 2025 * |
46.4x | P/E ratio 2026 * | 42.3x |
|---|---|---|---|---|---|
| Enterprise value | 371B 52.43B 45.07B 42.22B 39.35B 72.68B 4,718B 79.06B 494B 191B 2,228B 197B 193B 8,148B | EV / Sales 2025 * |
11.2x | EV / Sales 2026 * | 9.86x |
| Free-Float |
52.38% | Yield 2025 * |
0.45% | Yield 2026 * | 0.52% |
| 1 day | +0.60% | ||
| 1 week | -0.74% | ||
| Current month | -0.74% | ||
| 1 month | -0.55% | ||
| 3 months | -14.97% | ||
| 6 months | +14.37% | ||
| Current year | +34.25% |
| 1 week | 60.7 |  | 62.09 |
| 1 month | 59.31 | | 63.9 |
| Current year | 42.4 | | 74.04 |
| 1 year | 42.4 | | 74.04 |
| 3 years | 35.51 | | 74.04 |
| 5 years | 27 | | 97.39 |
| 10 years | 12.9 | | 97.39 |
| Manager | Title | Age | Since |
|---|---|---|---|
Jian Jun Liu
DFI | Director of Finance/CFO | 48 | 2021-11-18 |
Ji Feng
PSD | President | - | 2025-04-01 |
Yu Xu
CMP | Compliance Officer | 33 | 2021-05-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Jie Ping Sun
BRD | Director/Board Member | 55 | 2020-01-15 |
Hong Bin Dai
BRD | Director/Board Member | 49 | 2020-01-15 |
Piao Yang Sun
CHM | Chairman | 66 | 2021-07-07 |
| Name | Weight | AuM | Varia. Jan 1. | Investor |
|---|---|---|---|---|
 | 4.18% | 0 M€ | -19.71% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +0.60% | -0.74% | +25.88% | +54.51% | 57.93B | |
| -0.41% | -6.06% | +22.37% | +173.58% | 905B | |
| -0.27% | -2.41% | +35.05% | +12.95% | 487B | |
| -1.15% | -0.71% | +28.33% | +37.90% | 400B | |
| +0.26% | +1.14% | +21.30% | +0.44% | 330B | |
| +0.58% | -2.73% | +28.01% | +20.71% | 281B | |
| +0.19% | +2.49% | +18.48% | +24.80% | 255B | |
| -1.16% | -4.87% | -3.70% | -9.35% | 248B | |
| +1.24% | -2.33% | -59.84% | -31.25% | 214B | |
| -3.02% | -4.51% | +20.25% | +15.79% | 178B | |
| Average | -0.12% | -2.05% | +13.61% | +30.01% | 335.44B | |
| Weighted average by Cap. | -0.08% | -2.75% | +17.76% | +55.96% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 33.04B 4.67B 4.02B 3.76B 3.51B 6.48B 421B 7.05B 44.02B 17B 199B 17.54B 17.17B 726B | 36.88B 5.22B 4.48B 4.2B 3.92B 7.23B 469B 7.87B 49.13B 18.97B 222B 19.58B 19.16B 811B |
| Net income | 8.76B 1.24B 1.06B 997M 930M 1.72B 111B 1.87B 11.67B 4.5B 52.65B 4.65B 4.55B 193B | 9.65B 1.37B 1.17B 1.1B 1.02B 1.89B 123B 2.06B 12.86B 4.97B 58.03B 5.12B 5.02B 212B |
| Net Debt | -38.9B -5.5B -4.73B -4.43B -4.13B -7.63B -495B -8.3B -51.83B -20.01B -234B -20.65B -20.21B -855B | -45.77B -6.47B -5.56B -5.21B -4.86B -8.97B -583B -9.76B -60.98B -23.54B -275B -24.3B -23.78B -1,006B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 25-12-05 | 61.62 ¥ | +0.60% | 23,117,610 |
| 25-12-04 | 61.25 ¥ | +0.46% | 18,040,760 |
| 25-12-03 | 60.97 ¥ | -0.25% | 19,852,970 |
| 25-12-02 | 61.12 ¥ | -1.32% | 18,230,610 |
| 25-12-01 | 61.94 ¥ | -0.23% | 25,483,090 |
End-of-day quote Shanghai S.E., December 04, 2025
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- 600276 Stock
Select your edition
All financial news and data tailored to specific country editions
